
Delic Labs subsidiary of Delic Holdings Corp (OTCQB:DELCF) (CSE:DELC) (FRA: 6X0), received a Health Canada 56 research exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms, including MDMA, LSD, DMT, mescaline and 2C-B. Additionally, Delic Labs has received a Health Canada 56 exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs' latest exemptions enable the company to develop innovative analytical methods for psychedelic research.
